Bible says most oncologists would consider lenvatinib as a first-line therapy for patients who require systemic therapy where there are not suitable, focal palliative options.
Keith C. Bible, MD, PhD
Articles by Keith C. Bible, MD, PhD
Keith C. Bible, MD, PhD, professor of oncology, Mayo Clinic, discusses the challenges associated with treating patients with follicular cell-derived thyroid carcinoma.
Latest Updated Articles
Dr. Keith C. Bible on Treatments Beyond First-Line Lenvatinib in Thyroid CancerPublished: March 11th 2016 | Updated:
The Challenges of Treating Follicular Cell-Derived Thyroid CarcinomaPublished: January 28th 2015 | Updated: